Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment
| Autor: | Jean-François Delfraissy, Cécile Goujard, François Boué, Thérèse Croughs, Rodolphe Thiébaut, Christine Lacabaratz, Jean-Michel Molina, Yves Levy, Jean-Daniel Lelièvre, Stéphanie Beq, Véronique Avettand-Fenoel, Jean-Paul Viard, Geneviève Chêne, Christine Rouzioux, Laurence Weiss, Michel Morre |
|---|---|
| Přispěvatelé: | Service d'immunologie clinique [Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie antivirale systémique et cérébrale, Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne et maladies infectieuses, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Immunologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Henri-Mondor Albert-Chenevier, Hôpital Antoine Béclère, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Service de maladies infectieuses et tropicales [Saint-Louis], Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Cythéris, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Université Paris-Sud - Paris 11 ( UP11 ) -IFR93-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Henri-Mondor Albert-Chenevier, Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de Santé Publique, d'Epidémiologie et de Développement ( ISPED ), Guellaen, Georges |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
MESH: CD4 Lymphocyte Count
medicine.medical_treatment T-Lymphocytes Cell MESH : Aged MESH : Prospective Studies CD4-CD8 Ratio HIV Infections MESH: Cell Cycle Lymphocyte Activation MESH: Recombinant Proteins MESH: HIV-1 0302 clinical medicine Prospective Studies MESH: Aged 0303 health sciences MESH: Middle Aged Cell Cycle General Medicine Drug Tolerance MESH: HIV Infections MESH : Adult Cell cycle Middle Aged Recombinant Proteins 3. Good health medicine.anatomical_structure MESH: Immunologic Memory MESH : Lymphopenia Safety MESH : HIV-1 Research Article MESH : Interleukin-7 Adult MESH : Recombinant Proteins MESH : Immunologic Memory T cell MESH: Drug Tolerance MESH: Lymphopenia 03 medical and health sciences Antigen Lymphopenia MESH : Cell Cycle [SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biology MESH : CD4 Lymphocyte Count MESH : HIV Infections medicine Humans MESH : Middle Aged [SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology MESH : Safety MESH: Lymphocyte Activation [ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biology MESH : Lymphocyte Activation 030304 developmental biology Aged MESH : T-Lymphocytes MESH: Humans business.industry Interleukin-7 MESH : Humans MESH: Safety MESH: Adult Immunotherapy medicine.disease T cell deficiency MESH: Interleukin-7 MESH: Prospective Studies CD4 Lymphocyte Count MESH: T-Lymphocytes MESH : CD4-CD8 Ratio MESH : Drug Tolerance Immunology HIV-1 MESH: CD4-CD8 Ratio business Immunologic Memory CD8 030215 immunology |
| Zdroj: | Journal of Clinical Investigation Journal of Clinical Investigation, American Society for Clinical Investigation, 2009, 119 (4), pp.997-1007. ⟨10.1172/JCI38052⟩ Journal of Clinical Investigation, American Society for Clinical Investigation, 2009, 119 (4), pp.997-1007. 〈10.1172/JCI38052〉 |
| ISSN: | 0021-9738 |
| DOI: | 10.1172/JCI38052⟩ |
| Popis: | International audience; HIV infection results in CD4+ T cell deficiency, but efficient combination antiretroviral therapy (c-ART) restores T cells and decreases morbidity and mortality. However, immune restoration by c-ART remains variable, and prolonged T cell deficiency remains in a substantial proportion of patients. In a prospective open-label phase I/IIa trial, we evaluated the safety and efficacy of administration of the T cell regulator IL-7. The trial included 13 c-ART-treated HIV-infected patients whose CD4+ cell counts were between 100 and 400 cells/microl and plasma HIV RNA levels were less than 50 copies/ml. Patients received a total of 8 subcutaneous injections of 2 different doses of recombinant human IL-7 (rhIL-7; 3 or 10 microg/kg) 3 times per week over a 16-day period. rhIL-7 was well tolerated and induced a sustained increase of naive and central memory CD4+ and CD8+ T cells. In the highest dose group, 4 patients experienced transient increases in viral replication. However, functional assays showed that the expanded T cells responded to HIV antigen by producing IFN-gamma and/or IL-2. In conclusion, in lymphopenic HIV-infected patients, rhIL-7 therapy induced substantial functional and quantitative changes in T cells for 48 weeks. Therefore, patients may benefit from intermittent therapy with IL-7 in combination with c-ART. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|